Issue 3/2012
Content (16 Articles)
SCF and TLR4 ligand cooperate to augment the tumor-promoting potential of mast cells
Jing-Jing Wei, Chuan-Wang Song, Ling-Cong Sun, Ye Yuan, Dong Li, Bin Yan, Sheng-Jun Liao, Jian-Hua Zhu, Qi Wang, Gui-Mei Zhang, Zuo-Hua Feng
Wilms' tumor protein 1 (WT1) peptide vaccination in AML patients: predominant TCR CDR3β sequence associated with remission in one patient is detectable in other vaccinated patients
Sebastian Ochsenreither, Alberto Fusi, Anne Geikowski, David Stather, Antonia Busse, Andrea Stroux, Anne Letsch, Ulrich Keilholz
Role of CD44 in lymphokine-activated killer cell-mediated killing of melanoma
Jingping Sun, Gabriela P. Law, Robert J. McKallip
Integrin alphavbeta6 promotes tumor tolerance in colorectal cancer
Shao-Bo Yang, Yun Du, Ben-Yan Wu, Shi-Ping Xu, Jun-Bao Wen, Min Zhu, Chang-Hao Cai, Ping-Chang Yang
Design of immunogenic and effective multi-epitope DNA vaccines for melanoma
Hyun-Il Cho, Esteban Celis
Metronomic cyclophosphamide treatment in metastasized breast cancer patients: immunological effects and clinical outcome
Yingzi Ge, Christoph Domschke, Natalija Stoiber, Sarah Schott, Joerg Heil, Joachim Rom, Maria Blumenstein, Janina Thum, Christof Sohn, Andreas Schneeweiss, Philipp Beckhove, Florian Schuetz
In vivo electroporation restores the low effectiveness of DNA vaccination against HER-2/neu in aging
Mauro Provinciali, Alessandra Barucca, Elisa Pierpaoli, Fiorenza Orlando, Sara Pierpaoli, Arianna Smorlesi
A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
Osama E. Rahma, Ed Ashtar, Malgorzata Czystowska, Marta E. Szajnik, Eva Wieckowski, Sarah Bernstein, Vincent E. Herrin, Mortada A. Shams, Seth M. Steinberg, Maria Merino, William Gooding, Carmen Visus, Albert B. DeLeo, Judith K. Wolf, Jeffrey G. Bell, Jay A. Berzofsky, Theresa L. Whiteside, Samir N. Khleif
Activated human γδ T cells induce peptide-specific CD8+ T-cell responses to tumor-associated self-antigens
Bianca Altvater, Sibylle Pscherer, Silke Landmeier, Sareetha Kailayangiri, Barbara Savoldo, Heribert Juergens, Claudia Rossig
Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice
Angelos D. Gritzapis, Ioannis F. Voutsas, Constantin N. Baxevanis
Inclusive estimation of complex antigen presentation functions of monocyte-derived dendritic cells differentiated under normoxia and hypoxia conditions
Toshitatsu Ogino, Hideya Onishi, Hiroyuki Suzuki, Takashi Morisaki, Masao Tanaka, Mitsuo Katano
Gene silencing of TGF-β1 enhances antitumor immunity induced with a dendritic cell vaccine by reducing tumor-associated regulatory T cells
Helen Conroy, Karen C. Galvin, Sarah C. Higgins, Kingston H. G. Mills
Advances in cellular therapy: 6th international symposium on the clinical use of cellular products, March 24 and 25, 2011, Erlangen, Germany
Evelyn Ullrich, Jacobus Bosch, Michael Aigner, Simon Voelkl, Irena Kroeger, Petra Hoffmann, Marina Kreutz, Diana Dudziak, Armin Gerbitz
A rebuttal to the potential anti-tumour benefit of Helicobacter pylori-induced neutrophil-activating protein
Jannis Kountouras, Christos Zavos, Emmanuel Gavalas, Georgia Deretzi, Afroditi Tsona, Panagiotis Katsinelos, Savas Grigoriadis, Ioannis Pilpilidis, Dimitrios Tzilves, Elizabeth Vardaka, Konstantinos Mantzoukis, Stergios A. Polyzos
HP-NAP new therapy for bladder cancer: numquam periculum sine periculo vincitur
Gaia Codolo, Matteo Fassan, Mario M. D’Elios, Marina de Bernard
Response to the rebuttal letter of Kountouras and colleagues regarding the paper by Codolo et al. ‘HP-NAP inhibits the growth of bladder cancer in mice by activating a cytotoxic Th1 response’
Andrew M. Jackson, Hester A. Franks